000228752 001__ 228752
000228752 005__ 20230219174751.0
000228752 0247_ $$2CORDIS$$aG:(EU-Grant)860245$$d860245
000228752 0247_ $$2CORDIS$$aG:(EU-Call)H2020-MSCA-ITN-2019$$dH2020-MSCA-ITN-2019
000228752 0247_ $$2originalID$$acorda__h2020::860245
000228752 035__ $$aG:(EU-Grant)860245
000228752 150__ $$aInternational NETwork for training and innovations in THErapeutic RADiation$$y2019-09-01 - 2023-12-31
000228752 371__ $$aTU Dresden$$bTUD$$dGermany$$ehttp://tu-dresden.de/en$$vCORDIS
000228752 371__ $$aMaastricht University$$bUM$$dNetherlands$$ehttp://www.maastrichtuniversity.nl/$$vCORDIS
000228752 371__ $$aWESTDEUTSCHES PROTONENTHERAPIEZENTRUM ESSEN (WPE) GGMBH$$dGermany$$ehttp://www.wpe-uk.de$$vCORDIS
000228752 371__ $$aUniversity of Zurich$$bUZH$$dSwitzerland$$ehttp://www.uzh.ch/index_en.html$$vCORDIS
000228752 371__ $$aInstitute Curie$$bInstitute Curie$$dFrance$$ehttp://www.institut-curie.org/$$vCORDIS
000228752 371__ $$aTHE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD$$bUOXF$$dUnited Kingdom$$ehttp://www.ox.ac.uk$$vCORDIS
000228752 371__ $$aUniversité Catholique de Louvain$$bUCL$$dBelgium$$ehttp://www.uclouvain.be/en-index.html$$vCORDIS
000228752 371__ $$aUniversity of Duisburg-Essen$$bUniversity of Duisburg-Essen$$dGermany$$ehttps://www.uni-due.de/en/$$vCORDIS
000228752 372__ $$aH2020-MSCA-ITN-2019$$s2019-09-01$$t2023-12-31
000228752 450__ $$aTHERADNET$$wd$$y2019-09-01 - 2023-12-31
000228752 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000228752 680__ $$aRadiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training. 
The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care. 
Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.
000228752 909CO $$ooai:juser.fz-juelich.de:879181$$pauthority$$pauthority:GRANT
000228752 909CO $$ooai:juser.fz-juelich.de:879181
000228752 970__ $$aoai:dnet:corda__h2020::05dd9015d9e12068dce56b552f361c95
000228752 980__ $$aG
000228752 980__ $$aCORDIS
000228752 980__ $$aAUTHORITY